Brian O Mahony Shares Amit Nathwani’s Research from BIC 2025 on FVII and FIX Gene Therapies for Hemophilia
Brian O Mahony, CEO of Irish Haemophilia Society, Former President of WFH and EHC, shared on X:
”Nathwani from UCL BIC 2025 on their original FIX Gene Therapy trial.
First PWH now 15 years post. Average 13 years.
Stable expression of 2-5%FIX.ABR decreased from average 14 to 1.5. 7 of 10 off prophylaxis.
Reduction in ABR cumulative with decreased microbleeds and synovial inflammation over time.
2 unrelated malignancies. 1) PWH had liver biopsy at 10 years post- showed stable FIX transgene in liver in approximately 5% of hepatocytes transduced”
”Nathwani BIC 2025 on UCL plans to begin FVII Gene Therapy clinical trial in 2026.
Similar vector design as haemophilia B. cDNA small size at 1.4Kb so fits easily into AAV.Dose low at 6E11 vg/kg.
Eligible- severe FVII grade 3, at least 16 years of age, male or female
Interestingly, looking at cost only reimbursement model supported by foundations in UK and US so should be affordable if development works”
More from BIC 2025 featured in Hemostasis Today.
-
Aug 11, 2026, 04:10Haroun Gajraj: CLaCS vs Sclerotherapy – What Does the Evidence Show
-
Aug 11, 2026, 02:54Tareq Abadl: The Ultimate Guide to Clinically Significant Antibodies
-
Aug 10, 2026, 17:35Chokri Ben Lamine: Balancing Holistic Care and Precision in Hematology
-
Aug 10, 2026, 17:14Anna Stanizzi: Patient Blood Management as a New Model of Personalized Care
-
Aug 10, 2026, 17:12Odong Christopher: New Research on Ischemic Stroke Prediction in Uganda
-
Aug 10, 2026, 16:58Jeff Szer AM: Advancing the Management of Paroxysmal Nocturnal Hemoglobinuria
-
Aug 10, 2026, 16:51Suebsarn RuksakulpiwatÖ‰ A New Milestone in the Development of the Stroke Risk Screening Scales
-
Aug 10, 2026, 16:09Preetie Shetty Akkunje: Making Stroke Rehabilitation Accessible in Low-Resource Settings
-
Aug 10, 2026, 15:50The Next Antithrombotic Frontier: GPVI Inhibitors Beyond Aspirin